Hepatitis C infection among injection drug users in Stockholm Sweden: Prevalence and gender

References

• Swedish Institute for infectious Control. 2005. www.smittskyddsinstitutet.se.
   Google Scholar
• Bruandet A, Lucidarme D, Decoster A, Ilef D, Harbonnier J, Jacob C, et al. Incidence and risk factors of HCV infection in a cohort of intravenous drug users in the north and east of France. Rev Epidemiol Sante Publique 2006; 54: S15–22
   PubMed Web of Science ®Google Scholar
• Lucidarme D, Bruandet A, Ilef D, Harbonnier J, Jacob C, Decoster A, et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the north and east of France. Epidemiol Infect 2004; 132: 699–708
   PubMed Web of Science ®Google Scholar
• Maher L, Li J, Jalaludin B, Chant KG, Kaldor JM. High hepatitis C incidence in new injecting drug users: a policy failure?. Aust N Z J Public Health 2007; 31: 30–5
   PubMed Web of Science ®Google Scholar
• Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. J Clin Gastroenterol 2003; 36: 47–53
   PubMed Web of Science ®Google Scholar
• Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. American Journal of Epidemiology 2003; 157: 467–71
   PubMed Web of Science ®Google Scholar
• Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction (Abingdon, England) 2006; 101: 1499–508
   PubMed Web of Science ®Google Scholar
• Miller CL, Johnston C, Spittal PM, Li K, Laliberte N, Montaner JS, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology (Baltimore, Md.) 2002; 36: 737–42
   PubMed Web of Science ®Google Scholar
• Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis 2006; 6: 93
   PubMed Web of Science ®Google Scholar
• Brook MG. Sexually acquired hepatitis. Sex Transm Infect 2002; 78: 235–40
   PubMed Web of Science ®Google Scholar
• Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. Journal of Clinical Microbiology 1997; 35: 201–7
   PubMed Web of Science ®Google Scholar
• Network EPHCV. A significant sex – but not elective Caesarean section – effect on mother-to-child transmission of hepatitis C virus infection. The Journal of Infectious Diseases 2005;192:1872–9.
   PubMed Web of Science ®Google Scholar
• Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, et al. Gender differences in sexual and injection risk behaviour among active young injection drug users in San Francisco (the UFO Study). J Urban Health 2003; 80: 137–46
   PubMed Web of Science ®Google Scholar
• Seroconversion among young injection drug users: relationships and risks. The Journal of Infectious Diseases 2002;186:1558–64.
   PubMed Web of Science ®Google Scholar
• Doherty MC, Garfein RS, Monterroso E, Latkin C, Vlahov D. Gender differences in the initiation of injection drug use among young adults. J Urban Health 2000; 77: 396–414
   PubMed Web of Science ®Google Scholar
• Frajzyngier V, Neaigus A, Gyarmathy VA, Miller M, Friedman SR. Gender differences in injection risk behaviours at the first injection episode. Drug and Alcohol Dependence 2007; 89: 145–52
   PubMed Web of Science ®Google Scholar
• Montgomery SB, Hyde J, de Rosa CJ, Rohrbach LA, Ennett S, Harvey SM, et al. Gender differences in HIV risk behaviours among young injectors and their social network members. The American Journal of Drug and Alcohol Abuse 2002; 28: 453–75
   PubMed Web of Science ®Google Scholar
• Bennett GA, Velleman RD, Barter G, Bradbury C. Gender differences in sharing injecting equipment by drug users in England. AIDS Care 2000; 12: 77–87
   PubMed Web of Science ®Google Scholar
• Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. Journal of Viral Hepatitis 2006; 13: 34–41
   PubMed Web of Science ®Google Scholar
• Silini E, Bono F, Cividini A, Cerino A, Maccabruni A, Tinelli C, et al. Molecular epidemiology of hepatitis C virus infection among intravenous drug users. Journal of Hepatology 1995; 22: 691–5
   PubMed Web of Science ®Google Scholar
• Micalessi MI, Gerard C, Ameye L, Plasschaert S, Brochier B, Vranckx R. Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centres in Belgium, 2004–2005. Journal of Medical Virology 2008; 80: 640–5
   PubMed Web of Science ®Google Scholar
• Bowden M, Song L, Walt DR. Development of a microfluidic platform with an optical imaging microarray capable of attomolar target DNA detection. Analytical Chemistry 2005; 77: 5583–8
   PubMed Web of Science ®Google Scholar
• Darke S, Ross J, Teesson M, Lynskey M. Health service utilization and benzodiazepine use among heroin users: findings from the Australian Treatment Outcome Study (ATOS). Addiction (Abingdon, England) 2003; 98: 1129–35
   PubMed Web of Science ®Google Scholar
• Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. American Journal of Preventive Medicine 1998; 15: 1–8
   PubMed Web of Science ®Google Scholar
• Leroy V, Bourliere M, Durand M, Abergel A, Tran A, Baud M, et al. The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case-control study. European Journal of Gastroenterology & Hepatology 2002; 14: 485–9
   PubMed Web of Science ®Google Scholar